On May 6, 2026, CATALYST PHARMACEUTICALS, INC. entered into a merger agreement with Angelini Pharma, agreeing to buy the company for $31.50 per share, subject to stockholder approval and regulatory conditions. The merger is expected to close in Q3 2026, and includes provisions for executive and director voting support to favor the transaction.